FDA Final Guidance Sets a Stricter HBV Testing Floor for Blood Collections
The FDA has issued final guidance for blood establishments that collect whole blood, blood components, and Source Plasma, laying out recommendations for testing donations for hepatitis B virus to reduce the risk of transfusion-transmitted infection. The document is aimed squarely at the practical point where donor screening becomes patient protection: every unit that enters the blood supply carries a regulatory obligation to be checked for HBV before it can move downstream to transfusion or manufacturing use.
HBV occupies a special place in blood safety because it is explicitly treated as a relevant transfusion-transmitted infection. Under the regulatory framework cited in the guidance, establishments must test each donation of human blood or blood components for evidence of HBV infection, and they must use licensed, approved, or cleared screening tests in accordance with the manufacturer’s instructions. The guidance is meant to help blood centers meet those existing requirements while reducing the chance that an infected donation slips through the net.
A single missed donation can expose multiple recipients if the product is split, pooled, or used in manufacturing.
Testing Requirements Anchor the Guidance in Existing Federal Rules
The guidance does not create HBV screening from scratch. Instead, it interprets and operationalizes the requirements already embedded in 21 CFR 610.40, 21 CFR 610.41, and 21 CFR 630.40. That structure matters because it ties testing, donor deferral, and donor notification into one safety chain rather than treating them as separate administrative tasks. For blood establishments, the message is direct: if a donation is intended for transfusion or for use in manufacturing a product, including use in manufacturing a component of a medical device, HBV testing is not optional.
That regulatory link is clinically important. HBV remains a virus with efficient transmissibility in blood and a capacity to produce chronic infection, cirrhosis, and hepatocellular carcinoma. In transfusion medicine, the concern is not simply that an infected donation may transmit infection to one recipient; the larger concern is that blood is a high-stakes biologic product, and a single contaminated unit can create downstream harm that is both immediate and preventable. Testing recommendations in this setting function as a front-line barrier against that cascade.
The guidance applies to whole blood, blood components, and Source Plasma. By including Source Plasma, FDA is signaling that the same infection-control logic applies across collection pathways, even when the end use differs. Plasma destined for fractionation still needs to be screened with rigor because the public health premise is the same: donor-derived HBV must be intercepted before product release.
HBV Screening Sits at the Center of Transfusion Safety
The agency’s recommendation is not limited to a single assay name or one narrow workflow. Instead, it requires use of one or more screening tests that FDA has licensed, approved, or cleared, and it expects establishments to follow the test manufacturer’s instructions. In practice, that means a blood center’s assay strategy must fit both the regulatory framework and the performance characteristics of the available test system. The clinical objective is straightforward: reduce the risk of HBV transmission adequately and appropriately under federal standards.
HBV testing carries a broader public health function than simple donor qualification. It is part of an infection-control system that includes identifying infectious donations, deferring affected donors when indicated, and notifying donors when needed. Those steps protect the blood inventory today and help prevent future collections from the same donor when infection has not yet been recognized. The guidance therefore sits at the intersection of laboratory medicine, donor management, and patient safety.
In blood banking, timing of detection can be the difference between a discarded unit and a preventable transmission.
Operational Consequences for Blood Establishments
For collection centers, the practical burden is rooted in consistency. The guidance applies to every donation of human blood or blood components for transfusion or manufacturing use, which means screening protocols, specimen handling, test selection, and result interpretation must be reliable at scale. Any program that handles whole blood, red cells, platelets, or Source Plasma must be prepared to demonstrate that HBV testing is built into routine operations rather than layered on as an afterthought.
The final guidance also reinforces the regulatory expectation that establishments use testing methods appropriate to the risk being managed. That is not a theoretical distinction. A screening system in this setting must be able to support a blood supply that is both sufficiently available and sufficiently safe, and those demands can pull in different directions if programs are poorly organized. The regulatory text makes clear that adequacy and appropriateness are not abstract concepts; they are the standard by which HBV screening is judged.
Blood establishments that collect for transfusion or manufacturing should view the guidance as a compliance blueprint and a safety document at the same time. The same assay result that clears a unit for release also supports public trust in the blood supply. For clinicians who order transfusions, the promise is implicit but vital: the product delivered at the bedside has passed through a federally defined HBV screening pathway.
Docket Access and Public Comment Remain Open
FDA assigned the guidance docket number FDA-2024-D-5942 and made the final document available for download. Comments on the guidance can still be submitted online or in writing at any time under the agency’s comment process. The guidance lists the Center for Biologics Evaluation and Research as the issuing office and identifies blood products and biologics as the regulated product categories.
The document is current as of November 2, 2026, and is explicitly framed around testing for HBV as a means of reducing transfusion-transmitted infection risk. No new clinical trial data are presented here, and no patient cohort is described; the significance lies in the regulatory standard itself. For transfusion services, the key question is not whether HBV remains relevant. It is how completely each establishment can align its screening program with the federal expectation that every donation be tested and every infected unit kept out of the supply.